Dr. John Isaacs
Molecular Biology of Prostate Cancer
Professor of Oncology, JHU- School of Medicine
Professor of Urology, JHU-School of Medicine
Professor in the Cellular and Molecular Medicine Graduate Program, JHU-School of Medicine
Professor in Laboratory Training Program in Radiation Oncology and Molecular Radiation Sciences, JHU-School of Medicine
Professor in Anti-Cancer Drug Development Graduate Training Program, Department of Pharmacology and Molecular Science, JHU-School of Medicine
Professor in Chemical and Molecular Bioengineering, JHU- The Whiting School of Engineering
Member of Urological Oncology Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Member of Chemical Therapeautics Program, The Sidney Kimmel Comprehensive Cancer Center
Editor-in-Chief, The Prostate
Ph.D., Emory University, Atlanta, GA
Postdoctoral Fellow, Johns Hopkins School of Medicine
drug development specifically in prostate cancer
Molecular biology of prostate cancer, drug development in paraticular prostate cancer
Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007; 99:376-85.
Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT.
Amino acid containing thapsigargin analogues deplete androgen receptor protein via
synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 2009;
Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-
215050), a quinoline-3-carboxamide anti-angiogenic agent, modules the expression of
thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9:107.
Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-
generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate
cancer. Expert Opin Investig Drugs 2010; 19: 1235-43.
Dalrymple SL, Becker RE, Zhou H, DeWeese TL, and Isaacs JT. Tasquinimod Prevents the
Angiogenic Rebound Induced by Fractionated Radiation Resulting in an Enhanced
Therapeutic Response of Prostate Cancer Xenografts. Prostate 2012; 72: 638-48.
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-
expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol
Cancer Ther 2012; 11:257-66.
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B,
DeMarzo AM, Wilding G,Carducci MA, Dionne CA, Moller JV, Nissen P, Christensen
SB, Isaacs JT. Engineering a prostate-specific membrane antigen-activated tumor
endothelial cell prodrug for cancer therapy. Sci Transl Med 2012; 4:140ra86.
Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma associated
fibroblasts within the tumor stroma with a fibroblast activation protein (FAP)- activated
prodrug. JNCI 2012; 104 (September/ in press).
Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade
SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale
for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate.
2012 [Epub ahead of print]
Denmeade SR, Isaacs JT. Engineering Enzymatically Activated "Molecular Grenades" for
Cancer. Oncotarget 2012; (July 22/in press).